A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL<sup>®</sup>) in infants.

Authors:
Sharma H; Parekh S; Pujari P; Shewale S; Desai S and 24 more

Journal:
NPJ Vaccines

Publication Year: 2024

DOI:
10.1038/s41541-024-00828-w

PMCID:
PMC10881502

PMID:
38383584

Journal Information

Full Title: NPJ Vaccines

Abbreviation: NPJ Vaccines

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, Research & Experimental

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
4/6
66.7% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Competing interests The authors H.S., S.P., P.P., S.S., S.D., V.D., M.G., J.K.S., R.K., I.S. and S.G. are employees of Serum Institute of India Pvt. Ltd."

Evidence found in paper:

"The authors are grateful to the subjects and their parents for their participation and support. We thank the dedicated doctors and study staff at the participating study sites for implementing the study and providing patient care. We thank the data and safety monitoring board members for their valuable advice and guidance. The authors also acknowledge the study teams at Diagnosearch Lifesciences Pvt. Ltd., Mumbai, India, Metropolis Healthcare Ltd., Mumbai, India and Viroclinics Biosciences B.V., Rotterdam, Netherlands for their contributions to the study. This study was financially supported by Serum Institute of India Pvt. Ltd., Pune."

Evidence found in paper:

"Clinical Trial Registration – CTRI/2019/11/022052"

Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025